The Safety & Tolerability of INP104 is Currently Being Evaluated in the Company’s Recently Fully-Enrolled Pivotal Phase 3 “STOP-301” Trial New Data from a Patient Experience Survey Describe Dissatisfaction Levels with Current Available Treatments & Desire for New Options That Offer More Rapid & Complete Relief of Migraine Symptoms with a Lower Side Effect Profile SEATTLE, September...

SEATTLE, July 10, 2019 — Previously Reported STOP 101 Data, Including New Analysis Evaluating Cardiovascular Effects of Dihydroergotamine Mesylate (DHE) Delivered by Impel’s POD® Device, Support Bioavailability, Safety and Tolerability Profile of INP104 for Acute Migraine. Company’s Phase 3 Clinical Program Evaluating INP104 for the Treatment of Acute Migraine Nearing...

SEATTLE, April 30, 2019 — Safety, Tolerability and Comparative Bioavailability Data Support INP104, Impel’s Nasal Drug Candidate for Acute Migraine Results from the Company’s Phase 3 Clinical Program Evaluating INP104 for the Treatment of Acute Migraine Anticipated in Late 2019 Preclinical Data Support Selection of Company’s Novel Formulation of Nasal Levodopa,...

Crossover Financing to Advance Clinical Development of Central Nervous System Assets in Migraine, Parkinson’s Disease and Acute Agitation SEATTLE, December 6th, 2018 — Impel NeuroPharma (“Impel” or the “Company”), a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system (“CNS”) disorders with unmet medical needs,...